About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
IMGN - ImmunoGen| Previous Close | $3.56 | Open | $3.55 |
| Volume | 1.45M | Market Cap | 276.63M |
| Yield | Last Dividend |
| ImmunoGen Presents Final Data From Phase... | 09/17/20 |
| ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin?? at ESMO | |
| ImmunoGen Announces Webcast of Presentat... | 09/02/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference | |
| Warner Music acquires Israeli start-up I... | 08/18/20 |
| Tel Aviv and New York-based IMGN will continue to act as its own entity, helping Warner to build and track content on social media. | |
| Warner Music : IMGN Media Acquired by Wa... | 08/14/20 |
| Today it was announced that digital media company IMGN Media has been acquired by Warner Music Group. Founded in 2015, and headquartered in New York a... | |
| ImmunoGen Announces Inducement Grants Un... | 08/03/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| ImmunoGen (IMGN) Earnings: 2Q20 Key Numb... | 07/31/20 |
| ImmunoGen Inc. (NASDAQ: IMGN) reported second quarter 2020 earnings results today. Revenues were $15 million, compared to $15.5 million in the prior-y... | |
| ImmunoGen Reports Recent Progress and Se... | 07/31/20 |
| ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results | |
| ImmunoGen Announces Webcast of Presentat... | 07/29/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference | |
| ImmunoGen Appoints Susan Altschuller, Ph... | 07/20/20 |
| ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer | |
| ImmunoGen Announces Conference Call to D... | 07/16/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results | |
| ImmunoGen Presents Preclinical Data on I... | 06/22/20 |
| ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting | |
| ImmunoGen Announces Virtual 2020 Annual ... | 06/03/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders | |
| ImmunoGen Appoints Stacy Coen as Senior ... | 06/01/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer | |
| Why Is ImmunoGen (IMGN) Up 14.7% Since L... | 05/31/20 |
| ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| ImmunoGen Presents Initial Data at ASCO ... | 05/29/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine with Avastin?? in ... | |
| ImmunoGen Announces Webcast of Presentat... | 05/20/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference | |
| ImmunoGen to Present Preclinical Data on... | 05/14/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting | |
| ImmunoGen Announces Initial Data from FO... | 05/13/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab with Avastin in Recurrent Ovarian Canc... | |
| ImmunoGen Announces Webcast of Presentat... | 05/06/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming RBC Capital Markets Global Healthcare Virtual Conference | |
| ImmunoGen CEO Mark Enyedy speaks on prod... | 05/04/20 |
| COVID-19 has been pretty disruptive on clinical-level biotech and pharmaceutical companies worldwide, especially those running on tight budgets. Clini... | |
| ImmunoGen (IMGN) Q1 Earnings and Sales M... | 05/04/20 |
| ImmunoGen (IMGN) reports dismal first-quarter results. | |
| Immunogen Inc. (NASDAQ: IMGN) Q1 2020 Ea... | 05/01/20 |
| Immunogen Inc. (IMGN) Q1 2020 earnings call dated May 01, 2020 Corporate Participants: Courtney O???Konek ??? Senior Director of Corporate Communicati... | |
| ImmunoGen (IMGN) Reports Q1 Loss, Misses... | 05/01/20 |
| ImmunoGen (IMGN) delivered earnings and revenue surprises of -13.33% and -8.56%, respectively, for the quarter ended March 2020. Do the numbers hold c... | |
| ImmunoGen Reports Recent Progress and Fi... | 05/01/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results | |
| ImmunoGen Announces Conference Call to D... | 04/16/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its First Quarter 2020 Operating Results | |
| Why Is ImmunoGen (IMGN) Down 45.5% Since... | 03/15/20 |
| ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Sanofi just got its first cancer drug ap... | 03/03/20 |
| The French drugmaker Sanofi has officially re-entered oncology, as the Food and Drug Administration approved the multiple myeloma treatment Sarclisa o... | |
| ImmunoGen Beats Expectations and Fuels O... | 02/14/20 |
| Cost-cutting led to a surprise profit, and the company outlined the path ahead for its pipeline treatment for ovarian cancer. | |
| ImmunoGen (IMGN) Q4 Earnings and Revenue... | 02/14/20 |
| ImmunoGen (IMGN) delivered earnings and revenue surprises of 160.00% and 53.43%, respectively, for the quarter ended December 2019. Do the numbers hol... | |
| ImmunoGen Inc (IMGN): Q4 2019 Earnings S... | 02/14/20 |
| ??? ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected. ??? Revenue jumped th... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Option Attack | James Callyway | 61.00 % | Subscribe |
| Burdeshaw Investing | Matthew Burdeshaw | 55.00 % | Subscribe |
| Tech and Bio Swing Trades | Matthew Burdeshaw | 46.00 % | Subscribe |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
